ROSSARIRossari Biotech

₹650.1+0.81%

Market Cap

₹3,598.40 Cr

Stock P/E

26.34

ROCE

16.07%

ROE

12.25%

Book Value

₹225.98

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Q1 FY26 revenue grew 11.0% YoY to Rs. 543.7 crore, led by HPPC and AHN segments.
•
Capacity expansion assets are expected to deliver 3x-4x asset turnover and margin expansion as they ramp to full utilization.

NEGATIVES

•
Q1 CAPEX-related production downtime due to hot works and safety protocols weighed on output.
•
Institutional and B2C business posted a loss in Q1, pressuring consolidated margins.

Peers Summary

Sector Leader

Rossari Biotech Ltd. demonstrates solid growth and profitability metrics relative to its peers, with reasonable valuation ratios. It stands out in revenue growth and debt management, making it a strong competitor in the chemicals industry.

Key Points

• Rossari Biotech Ltd. shows the highest revenue growth (YoY) at 13.64%.
• It has a low debt-to-equity ratio of 0.1013, indicating strong financial health.
• The PEG ratio of 1.39 suggests Rossari is reasonably valued given its growth prospects.

Top Performers

Solar Industries India Ltd.

Highest ROE at 29.59% and strong EPS growth.

Pidilite Industries Ltd.

Strong ROE and profitability margins, albeit at a high PE.

Explore

Watchlists

Command Palette